Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma

Yucai Wang; Matthew J Maurer; Melissa C Larson; Cristine Allmer; Andrew L Feldman; N Nora Bennani; Carrie A Thompson; Luis F Porrata; Thomas M Habermann; Thomas E Witzig; Stephen M Ansell; Susan L Slager; Grzegorz S Nowakowski; James R Cerhan

doi:10.1111/bjh.15997

Back

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma

Journal article

Open access

Peer reviewed

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma

Yucai Wang, Matthew J Maurer, Melissa C Larson, Cristine Allmer, Andrew L Feldman, N Nora Bennani, Carrie A Thompson, Luis F Porrata, Thomas M Habermann, Thomas E Witzig, …

British journal of haematology, Vol.186(6), pp.820-828

09/2019

DOI: 10.1111/bjh.15997

PMCID: PMC6731132

PMID: 31135975

Files and links (1)

url

https://doi.org/10.1111/bjh.15997View

Published (Version of record) Open Access

Abstract

The diabetes mellitus (DM) drug metformin targets mechanistic/mammalian target of rapamycin and inhibits lymphoma growth in vitro. We investigated whether metformin affected outcomes of newly diagnosed diffuse large B-cell (DLBCL, n = 869) and follicular lymphoma (FL, n = 895) patients enrolled in the Mayo component of the Molecular Epidemiology Resource cohort study between 2002 and 2015. Hazard ratios (HR) and 95% confidence intervals (CIs) adjusted for age, sex, body mass index, prognostic index and treatment were used to estimate the association of metformin exposure (No DM/No metformin; DM/No metformin; DM/Metformin) with event-free (EFS), lymphoma-specific (LSS) and overall (OS) survival. Compared to No DM/No metformin DLBCL patients, there was no association of DM/Metformin (n = 48; HR = 1·05, 95% CI 0·59-1·89) or DM/No metformin(n = 54; HR = 1·41, 95% CI 0·88-2·26) with EFS; results were similar for LSS and OS. Compared to No DM/No metformin FL patients, there was no association of DM/Metformin (n = 37; HR = 1·16, 95% CI 0·71-1·89) or DM/No metformin (n = 19; HR = 1·16, 95% CI 0·66-2·04) with EFS; results were similar for LSS. However, DM/Metformin was associated with inferior OS (HR = 2·17; 95% CI 1·19-3·95) compared to No DM/No metformin. In conclusion, we found no evidence that metformin use was associated with improved outcomes in newly diagnosed DLBCL and FL.

mTOR

metformin

diabetes mellitus

diffuse large B-cell lymphoma

follicular lymphoma

Details

Title: Subtitle: Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma
Creators: Yucai Wang - Mayo Clinic
Matthew J Maurer - Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
Melissa C Larson - Mayo Clinic
Cristine Allmer - Mayo Clinic
Andrew L Feldman - Mayo Clinic
N Nora Bennani - Mayo Clinic
Carrie A Thompson - Mayo Clinic
Luis F Porrata - Mayo Clinic
Thomas M Habermann - Mayo Clinic
Thomas E Witzig - Mayo Clinic
Stephen M Ansell - Mayo Clinic
Susan L Slager - Mayo Clinic
Grzegorz S Nowakowski - Mayo Clinic
James R Cerhan - Mayo Clinic
Resource Type: Journal article
Publication Details: British journal of haematology, Vol.186(6), pp.820-828
DOI: 10.1111/bjh.15997
PMID: 31135975
PMCID: PMC6731132
ISSN: 0007-1048
eISSN: 1365-2141
Grant note: U01 CA195568 / NCI NIH HHS P30 CA086862 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
Language: English
Date published: 09/2019
Academic Unit: Epidemiology
Record Identifier: 9984368218402771

Metrics

8 Record Views

16 Times Cited - Web of Science

See more details